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LETTERS TO THE EDITOR
Angiosarcoma Arising
from Right Atrium
Remarkable Response to
Concurrent
Chemoradiotherapy with
Carboplatin and
Paclitaxel
To the Editor:
We read with interest the case re-
port by Fehr et al.1 and the concise review
by Orlandi et al.2 regarding cardiac sarco-
mas. Concurrent chemoradiotherapy
(CRT) to cardiac angiosarcomas has been
scarcely documented, and only one case
was reported with the benefit from con-
current CRT with docetaxel.3 Although
efficacy of weekly paclitaxel (PTX) for
unresectable angiosarcoma has been dem-
onstrated,4 CRTwith weekly PTXwas not
reported before the report by Fehr et al. We
present herein a case of metastatic angiosar-
coma arising from the right atrium, which
remarkably responded to concurrent CRT
with weekly carboplatin and PTX.
A 40-year-old man was referred to
our institute, presenting a tumor in the right
atrium and multiple bilateral lung nodules
with the computed tomography (Figures 1A,
B). Histology obtained by wedge resection
of a lung nodule revealed a high-grade epi-
thelial angiosarcoma, thus the patient was
diagnosed with angiosarcoma from right
atrium with multiple lung metastases. We
judged it to be unresectable and decided to
perform concurrent CRT (30 fractions of
2Gy) with weekly carboplatin (area under
the curve  2) and PTX (60 mg/m2) for 6
consecutive weeks. The radiation field was
limited to the primary cardiac tumor. After
the therapy, almost all bilateral pulmonary
nodules disappeared, and a large tumor in
the right atriumwas markedly reduced (Fig-
ure 2A,B). Although grade 2 esophagitis and
neutropenia were observed, the treatment
was generally well tolerated. No evidence of
progression has been confirmed after more
than 5 months of follow-up.
Multimodality treatment combined
with surgery and adjuvant chemotherapy
and/or radiotherapy is indicated as the stan-
dard care for patients with cardiac angiosar-
comas.Nevertheless, themajority of patients
with cardiac sarcoma are already unresect-
able and metastatic disease at their initial
diagnosis and have a poor prognosis. CRT is
desirable in some cases with cardiac sar-
coma to control both the primary cardiac
tumor and metastatic lesions. In our case, a
combined regimen including PTX was cho-
sen to obtain better response of metastatic
lesions, and good response was clearly ob-
served. Moreover, the efficacy and tolerabil-
ity of concurrent CRT with carboplatin 
PTX have been recently demonstrated in
locally advanced non-small cell lung can-
cer.5 To our knowledge, this is the first
report demonstrating the efficacy of concur-
rent CRT with carboplatin  PTX for car-
diac angiosarcoma. Nevertheless, there is no
other evidence of CRT with doublet regi-
mens. Future studies to explore usefulness of
concurrent CRT for cardiac angiosarcomas
are warranted.
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FIGURE 1. A, Arrows indicate bilateral pulmonary metastases before the treat-
ment. B, A huge cardiac tumor in the right atrium before the treatment is shown.
FIGURE 2. A, Almost all bilateral pulmonary nodules disappeared 3 months after
the initiation of chemoradiation therapy. B, The cardiac tumor in the right atrium
was remarkably reduced 3 months after the initiation of chemoradiation therapy.
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Chemotherapy Dose
Intensity and Survival
in Non-small Cell Lung
Cancer
To the Editor:
Brunetto et al.1 noted that modest
chemotherapy dose reductions did not
have any major impact on survival in
patients with non-small cell lung cancer
(NSCLC) treated with platinum-doublet
chemotherapy and proposed that this
might be due to comorbidities, the impact
of resistance factors such as excision
repair cross-complementing rodent re-
pair deficiency, complementation group
1 (ERCC1) ormarked sensitivity to therapy
in some of the responders. We had previ-
ously converted response rates into hypo-
thetical mean percent tumor cell kill for a
large number of published clinical trials in
NSCLC and had used nonlinear regression
analysis to assess the relationship between
hypothetical log mean cell kill and planned
dose intensity.2 For all platinum combina-
tions assessed, dose-response curves flat-
tened at higher chemotherapy doses. Low
chemotherapy doses were better than no
therapy, but high doses were no better than
low doses.
We had previously hypothesized
that one could infer resistance mecha-
nisms from the shape of the dose-response
curve and that presence of a resistance
factor (e.g., the ERCC1 mentioned by
Brunetto et al.) would give a shoulder on
the dose-response curve when log cell
survival was plotted against linear doses
(analogous to competitive inhibition of
drug effect).3 Mutation of an obligate tar-
get or activating system, would give a
reduced slope on the curve, analogous to
decreased affinity of a drug for its target.3
Deficiency or saturation of something re-
quired for drug effect (e.g., a drug uptake or
activating system, proapoptotic factors, or
cells in a sensitive phase of the cell cycle)
would give an initial downward slope fol-
lowed by a terminal plateau (analogous to
noncompetitive inhibition of drug effect).3
On the basis of our hypothesis and on
our observation of the flattening of the dose-
response curve in NSCLC, we postulated
that our inability to cure metastatic NSCLC
with chemotherapy is ultimately due to de-
ficiency or saturation of something required
for drug efficacy. Furthermore, as no meta-
static epithelial cancer can be cured even by
high-dose chemotherapy, we hypothesized
that all epithelial cancers (e.g., breast, colo-
rectal, and lung cancers) may share a com-
mon reason for this incurability.2 For differ-
ent epithelial cancers or for different patients
with the same type of cancer, a higher or
lowermaximum cell kill may be achievable,
and it may take fewer or more drugs or
higher or lower doses to achieve this maxi-
mum cell kill, but the outcome is ultimately
the same. Resistance factors such as ERCC1
could affect degree of palliation in individual
patients but would not in themselves be
responsible for incurability.
A corollary of this is that, even if all
epithelial cancers are incurable when meta-
static, higher drug doses, or addition ofmore
agents may be useful for relatively sensitive
tumors such as breast and small cell lung
cancer (SCLC) but would be much less
useful for more resistant tumors such as
NSCLC and pancreatic cancer. In keeping
with this, when we did the same type of
analysis in SCLC as in NSCLC, the maxi-
mum achievable cell kill was greater in
SCLC, and cell kill seemed to keep increas-
ing over awider dose range, but amaximum
possible cell kill was nevertheless ultimately
reached.4
A second corollary is that if we
are correct that a common mechanism is
responsible for the incurability of all
epithelial malignancies, then a single
new approach targeting this mechanism
could similarly have a dramatic impact
on outcome of a broad spectrum of ep-
ithelial malignancies.
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Clinical Significance of
Serum Vascular
Endothelial Growth
Factor in Malignant
Pleural Mesothelioma
To the Editor:
We read with great interest the arti-
cle by Yasumitsu et al.,1 who reported the
clinical significance of serum vascular en-
dothelial growth factor (VEGF) in malig-
nant pleural mesothelioma (MPM). VEGF
is an important regulator of angiogene-
sis and might have critical roles in MPM
progression. Demirag et al.2 demon-
strated a significant correlation between
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